Cinqair Patent Expiry and Market Status for 2025-2026
As of 2025 and 2026, Cinqair (reslizumab) is expected to remain on the market, with its patent protection still largely in place. DrugPatentWatch.com indicates that the earliest anticipated patent expiry for Cinqair is in 2030, suggesting that generic competition is unlikely before then [1]. This extended patent exclusivity allows the innovator company, Teva Pharmaceuticals, to maintain its market position for Cinqair.
What is Cinqair Used For?
Cinqair is a prescription medication used to treat severe eosinophilic asthma [2]. It is an interleukin-5 (IL-5) antagonist, a type of monoclonal antibody that targets and inhibits IL-5, a protein that plays a key role in the inflammatory process of eosinophilic asthma [3]. By reducing eosinophils in the airways, Cinqair helps to decrease asthma exacerbations [2].
How Does Cinqair Work?
Cinqair works by binding to interleukin-5 (IL-5) [3]. IL-5 is a cytokine that is essential for the development, activation, and survival of eosinophils. In patients with eosinophilic asthma, high levels of IL-5 lead to an increase in eosinophils, which contribute to airway inflammation, hyperresponsiveness, and mucus production [4]. By blocking IL-5, reslizumab prevents these events, thereby reducing eosinophilic inflammation in the lungs [3][4].
When Can Generic Cinqair Be Launched?
The launch of generic Cinqair is tied to the expiration of its patents. According to DrugPatentWatch.com, the earliest a patent related to Cinqair is set to expire is in 2030 [1]. This means that generic versions of reslizumab are not expected to be available before this date, barring any successful patent challenges or early settlements.
Are There Other Treatments for Severe Eosinophilic Asthma?
Yes, there are other treatment options for severe eosinophilic asthma. These include other biologic therapies that target different pathways involved in the disease. For instance, drugs like mepolizumab (Nucala) and benralizumab (Fasenra) also target IL-5, but through different mechanisms or binding sites than reslizumab [5][6]. Dupilumab (Dupixent) is another biologic that targets the IL-4 and IL-13 pathways, which are also implicated in eosinophilic inflammation [7]. The choice of treatment depends on individual patient characteristics and physician recommendation.
What Are the Side Effects of Cinqair?
Common side effects reported with Cinqair include upper respiratory tract infections, nasopharyngitis, and oropharyngeal pain [2]. More serious, though less common, side effects can include hypersensitivity reactions, anaphylaxis, and cardiac events [2]. Patients should discuss potential risks and benefits with their healthcare provider.
What Are the Clinical Trial Results for Cinqair?
Clinical trials for Cinqair, such as the SUMMIT 1 and SUMMIT 2 studies, demonstrated that reslizumab significantly reduced the rate of asthma exacerbations in patients with severe eosinophilic asthma compared to placebo [8][9]. The trials also showed improvements in lung function and symptom control in treated patients [8][9].
Sources
1. DrugPatentWatch.com
2. Cinqair Prescribing Information
3. "Reslizumab." National Library of Medicine, U.S. National Institutes of Health.
4. "Eosinophilic Asthma." National Heart, Lung, and Blood Institute, U.S. Department of Health and Human Services.
5. Nucala Prescribing Information
6. Fasenra Prescribing Information
7. Dupixent Prescribing Information
8. Busse, W. W., et al. (2015). Randomized trial of reslizumab in adults with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology, 135(3), 619-626.e5.
9. Corren, J., et al. (2016). Reslizumab in patients with severe eosinophilic asthma without an oral corticosteroid–sparing strategy. The Journal of Allergy and Clinical Immunology: In Practice, 4(6), 1133-1141.e4.